Intended for US healthcare professionals only.

Resources

In this section, you’ll find a variety of resources to help you better understand Optune, share this novel treatment with your patients who have newly diagnosed or recurrent glioblastoma (GBM), and start prescribing Optune.

Print Resources for Your Practice

Long-Term Quality Survival Brochure

Learn about Optune + temozolomide (TMZ) for patients with newly diagnosed GBM.

View this PDF

nCompass® Brochure

See the nCompass brochure for more information and patient support to learn how nCompass supports patients at every step of their journey.

View this PDF

Optune for Elderly Patients

Learn about Optune + TMZ in elderly patients with histologically-confirmed, newly diagnosed GBM.

View this PDF

Management Guidelines for Dermatologic Adverse Events (dAEs) Brochure

This brochure provides guidance to you and your practice for identifying, preventing, and managing dAEs for Optune users.

View this PDF

Monthly Usage Fact Sheet

Learn how a greater survival benefit was achieved with increased Optune use.

View this PDF

Optune for Biopsy-Only Patients

Learn about Optune + TMZ in biopsy only patients.

View this PDF

Print Resources for Patients

Optune Patient Brochure

Provides a high-level overview of Optune, including clinical efficacy, how to obtain and properly use Optune, and the nCompass Support Program.

View this PDF

Support Offerings Brochure

Explains the peer-to-peer patient program that connects Optune users and patients/caregivers who are considering, are about to start, or have recently started Optune.

View this PDF

nCompass® Patient Brochure

An in-depth look at nCompass from the first Welcome Call to ongoing support and education throughout treatment.

View this PDF

Mylink™ Quick Reference Card

Introduces patients to the MyLink hardware and provides a step-by-step guide of how to use it.

View this PDF

Patient Scalp Care Guidelines

Answers your patients’ questions about scalp care and transducer array placement.

View this PDF

Optune Troubleshooting Tips

A guide for patients and caregivers to refer to when the Optune device alarm goes off to easily determine and address the cause.

View this PDF

Patient Travel Support by nCompass Brochure

Answers frequently asked questions about travel and provides checklists of what to pack and bring when traveling with Optune.

View this PDF

Optune Dialogue Tear Pad

Find patient-friendly language to assist you in discussing Optune with patients and caregivers.

View this PDF

Additional Resources

Peer-Reviewed Publications

Review various publications about Optune.

See publications

Calendar of Events

Optune open houses and events focused on brain cancer.

See upcoming events

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.

Read more

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.